Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Basic Experimental Studies with Human Required)

The Stephen I. Katz Early Stage Investigator Research Project Grant is administered by the National Institutes of Health within the U.S. Department of Health and Human Services. Multiple NIH Institutes and Centers participate, reflecting a broad federal commitment to advancing biomedical and behavioral research. This funding opportunity is specifically designed to support early stage investigators who are proposing innovative research in a new scientific direction that differs from their prior work. The program was established to encourage scientific risk-taking and to stimulate novel approaches that may not yet have preliminary supporting data. The primary purpose of this grant is to fund basic experimental studies involving human participants that contribute to fundamental knowledge about biological or behavioral phenomena. These studies must meet the NIH definition of both a clinical trial and basic research, meaning that participants are prospectively assigned to interventions or conditions, but the research is not intended to develop specific products or applied outcomes. The program emphasizes conceptual innovation, encouraging investigators to pursue transformative ideas that advance scientific understanding rather than incremental progress. Funding under this opportunity is flexible in structure. There is no predefined budget cap, and applicants are instructed to request funds that align with the actual needs of their proposed project. The maximum project period is five years, allowing investigators sufficient time to execute complex experimental designs. There is no cost sharing or matching requirement associated with this program. Allowable costs and restrictions follow standard NIH Grants Policy Statement guidelines, including provisions for pre-award costs and compliance with federal regulations governing research involving human subjects. Eligibility is broad and includes a wide range of U.S.-based institutions such as higher education institutions, nonprofit organizations, for-profit entities, small businesses, and various levels of government. However, all applicants must be domestic entities, as foreign organizations and foreign components are not eligible. The principal investigator must qualify as an Early Stage Investigator as defined by NIH, and the proposed research must clearly represent a departure from their previous work. Applications that include preliminary data are considered noncompliant and will not be reviewed. The application process requires submission through approved electronic systems such as Grants.gov or the NIH ASSIST platform. Applicants must follow the detailed instructions provided in the NIH application guide, including required attachments such as a one-page “New Research Direction” statement explaining how the proposed work differs from prior research. Additional components include a research strategy outlining significance, innovation, and approach, as well as compliance with data management and sharing policies. Strict adherence to formatting and submission requirements is enforced, and noncompliant applications may be rejected without review. Applications are evaluated through the NIH peer review process based on criteria including significance and innovation, scientific rigor and feasibility, and investigator expertise and environment. Reviewers assess the potential for the project to generate impactful knowledge and consider whether the proposed change in research direction is meaningful and justified. Additional considerations include human subjects protections, study design quality, and institutional support. Funding decisions are ultimately based on merit, availability of funds, and alignment with NIH program priorities. The funding opportunity follows a recurring submission schedule with multiple application due dates each year. The current cycle includes deadlines such as January, May, and September, with review and award timelines extending several months beyond submission. Applications are typically due by 5:00 PM local time of the applicant organization. The opportunity is currently active, with a closing date in May 2026 for the next submission cycle. Awards are expected to begin approximately six to nine months after submission, depending on the review cycle.

Ensure proposal clearly demonstrates a new research direction and excludes preliminary data; emphasize innovation and strong conceptual framework; align with NIH institute mission